Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.
Saved in:
| Title: | Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia. |
|---|---|
| Authors: | Moore CG; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Chyong DI; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Daver N; MD Anderson Cancer Center, Houston, Texas, USA., Aubrey BJ; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Marx KR; MD Anderson Cancer Center, Houston, Texas, USA., Takahashi K; MD Anderson Cancer Center, Houston, Texas, USA., Abaza Y; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Smith CC; University of California San Francisco, San Francisco, California, USA., Amrein PC; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Hock H; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Hobbs G; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Narayan R; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Lee MH; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Moran JA; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Bergeron M; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Foster JE; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Perl AE; University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA., Levis MJ; Johns Hopkins Cancer Center, Baltimore, Maryland, USA., DiNardo CD; MD Anderson Cancer Center, Houston, Texas, USA., Brunner AM; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Fathi AT; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. |
| Source: | British journal of haematology [Br J Haematol] 2026 Jul 12. Date of Electronic Publication: 2026 Jul 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
